Hims & Hers Soars 33% on Novo Nordisk’s Wegovy Lifeline—Because Nothing Cures Market Jitters Like Big Pharma’s Pocketbook
Hims & Hers stock just staged a Lazarus-like recovery—up 33% from its lows—after inking a deal with Novo Nordisk for Wegovy distribution. The market’s sudden faith in telehealth? Cynics would say it’s less about innovation and more about riding Big Pharma’s coattails.
Wall Street’s latest love affair proves once again: when in doubt, bet on the company that knows how to monetize your insecurities. Bonus points if they’ve got a Danish sugar daddy bankrolling the operation.
Early 2025 Rally Fades, but Technical Support Holds
At the beginning of the year, Hims & Hers Health stock experienced a powerful rally, surging past $73 in early February amid growing investor enthusiasm for digital health solutions. However, as broader market sentiment deteriorated, particularly across growth-oriented stocks, HIMS began a steady descent. By the end of April, shares had dropped to $28.48, brushing against key technical support at the 200-day simple moving average, which hovered around $25.
That level held firm, and late last week, the stock began reversing higher — a move that gained serious traction today.
Massive Bullish Gap After Wegovy Partnership
On Tuesday, HIMS shares exploded over 26% higher at the open, surging to $37 in response to a major business development, while climbing 33% in several days. The company announced a new collaboration with Danish pharmaceutical heavyweight Novo Nordisk (NVO), aimed at offering the blockbuster weight-loss drug Wegovy to Hims & Hers’ customers via its telehealth platform.
HIMS Stock Chart Daily – Pushing Above MAs
Starting this week, users will be able to purchase a bundled package that includes a full range of Wegovy doses along with a Hims & Hers membership, priced from $599. The partnership significantly expands the company’s weight-loss treatment offerings, addressing a growing demand in the digital health market.
Earlier this month, Hims & Hers had also revealed plans to make branded tirzepatide — the active ingredient in Eli Lilly’s Zepbound and Mounjaro — available through its platform. Eli Lilly was quick to clarify that it has no direct relationship with Hims & Hers, emphasizing that licensed providers may prescribe its medications independently.
Stock Nearly Triples Over the Year, Q1 Earnings Ahead
Thanks to today’s surge, HIMS stock has now nearly tripled over the past 12 months, reflecting increasing investor interest in telehealth and prescription wellness solutions. The timing of this announcement is particularly strategic, as the company is scheduled to report its first-quarter earnings next Monday.
With growing traction in the weight-loss drug market and consumer demand surging for accessible health options, investors will be closely watching whether Hims & Hers can translate this momentum into revenue growth and long-term profitability.
